Posted by vanvog on April 20, 2013, at 2:06:04
In reply to Re: Parnate Brands/Manufacturers, posted by Tyrannosaur on April 20, 2013, at 0:04:02
AJN, American Journal of Nursing:
January 2000 - Volume 100 - Issue 1, PART 1 OF 2 - p 71
Drug Watch----------------------------
MAOI PRESCRIPTIONS: Way down, but still not out
Only 2% of psychiatrists recently surveyed reported prescribing monoamine oxidase inhibitors (MAOIs) frequently. This is down from 25% 10 years ago, before the widespread use of selective serotonin reuptake inhibitors (SSRIs).
The most common explanation for never or rarely prescribing MAOIs was potential interactions. Other reasons were side effects, a preference for other drugs, potential legal complications, the dietary restrictions required for patients receiving MAOIs, lack of training regarding their use, and lack of belief in their efficacy.
Meanwhile, the majority of respondents, 92%, acknowledged the usefulness of MAOIs for treating atypical depression, and a substantial percentage found them useful for major depression (melancholic type), panic disorder, social phobia, and other disorders. They are particularly useful for patients who don't respond to SSRIs and can't tolerate the side effects associated with tricyclic antidepressants.
MAOIs are prescribed infrequently, but it's important to be aware of their potential side effects (such as postural hypotension, insomnia, and headache) and the risk of hypertensive crisis with concomitant sympathomimetics, levodopa, and high-tyramine foods such as cheese, chocolate, wine, beer, and coffee.
Source: Balon R, et al. A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr Serv 1999;50(7):945-47. Full text: http://psychiatryonline.org/data/Journals/PSS/3519/945.pdf
----------------------------
poster:vanvog
thread:1042344
URL: http://www.dr-bob.org/babble/20130408/msgs/1042380.html